Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Piqray
|
| gptkbp:activities |
P I3 K inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Piqray
|
| gptkbp:can_be_used_with |
gptkb:letrozole
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:developed_by |
gptkb:Novartis
|
| gptkbp:effective_date |
gptkb:2019
|
| https://www.w3.org/2000/01/rdf-schema#label |
alpelisib
|
| gptkbp:indication |
gptkb:HR-positive_breast_cancer
|
| gptkbp:ingredients |
C22 H24 N4 O3 S
|
| gptkbp:is_used_for |
gptkb:healthcare_organization
|
| gptkbp:manager |
oral
|
| gptkbp:side_effect |
fatigue
nausea diarrhea rash hyperglycemia |
| gptkbp:targets |
P I3 K pathway
|